UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Nature communications, 2018-03, Vol.9 (1), p.896-10, Article 896

2018

Volltextzugriff (PDF)

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

The lancet oncology, 2017-07, Vol.18 (7), p.929-945

2017

Volltextzugriff (PDF)

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

The lancet oncology, 2007-02, Vol.8 (2), p.119-127

2007

Volltextzugriff (PDF)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study

Breast cancer research : BCR, 2022-09, Vol.24 (1), p.61-61, Article 61

2022

Volltextzugriff (PDF)

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Breast cancer research : BCR, 2023-04, Vol.25 (1), p.39-39, Article 39

2023

Volltextzugriff (PDF)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

Breast cancer research : BCR, 2019-12, Vol.22 (1), p.2-20, Article 2

2019

Volltextzugriff (PDF)

Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer

Trials, 2022-05, Vol.23 (1), p.372-372, Article 372

2022

Volltextzugriff (PDF)

Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design

Trials, 2021-06, Vol.22 (1), p.397-397, Article 397

2021

Volltextzugriff (PDF)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R46-R46, Article R46

2012

Volltextzugriff (PDF)

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

NPJ breast cancer, 2021-02, Vol.7 (1), p.11-11, Article 11

2021

Volltextzugriff (PDF)

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10099), p.1048-1060

2017

Volltextzugriff (PDF)

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2022-05, Vol.327 (20), p.1963

2022

Volltextzugriff (PDF)

Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial – Authors' reply

The Lancet (British edition), 2024-05, Vol.403 (10438), p.1752-1752

2024

Volltextzugriff (PDF)

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Radiotherapy and oncology, 2016-07, Vol.120 (1), p.114-118

2016

Volltextzugriff (PDF)

Accelerated partial breast irradiation: more questions than answers?

The Lancet (British edition), 2019-12, Vol.394 (10215), p.2127-2129

2019

Volltextzugriff (PDF)

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial

The lancet oncology, 2006-06, Vol.7 (6), p.467-471

2006

Volltextzugriff (PDF)

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

The Lancet (British edition), 2023-06, Vol.401 (10394), p.2124-2137

2023

Volltextzugriff (PDF)

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer

Cancer discovery, 2024-02, Vol.14 (2), p.274-OF16

2024

Volltextzugriff (PDF)

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

Research involvement and engagement, 2018-07, Vol.4 (1), p.22-22, Article 22

2018

Volltextzugriff (PDF)

Radiotherapy for breast cancer, the TARGIT-A trial

The Lancet (British edition), 2014-05, Vol.383 (9930), p.1716-1717

2014

Volltextzugriff (PDF)

Targeted radiotherapy for early breast cancer – Authors' reply

The Lancet (British edition), 2018-01, Vol.391 (10115), p.27-28

2018

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

ThemaAged

ThemaBreast Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients

Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

Can patient decision aids reduce decisional conflict in a de-escalation of breast radiotherapy clinical trial? The PRIMETIME Study Within a Trial implemented using a cluster stepped-wedge trial design

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial – Authors' reply

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Accelerated partial breast irradiation: more questions than answers?

Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

Radiotherapy for breast cancer, the TARGIT-A trial

Targeted radiotherapy for early breast cancer – Authors' reply

Aktive Filter

Suchergebnisse filtern